Boehringer Begins Dosing Trial of AD Treatment

Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody for the treatment of Alzheimer’s disease. The start of the Phase I study triggers a milestone payment of 5 million Euros to development partner Ablynx.

The trial involves a single-center, partially randomized, single-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenous and subcutaneous injections with the Nanobody in healthy subjects. The trial is expected to recruit 80 healthy volunteers and results are anticipated during 2H14.

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer’s disease using Ablynx’s Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialization of any products resulting from the collaboration.